GLP-1 Drug Options: Biomarker Context & Personalization

Last reviewed: May 20, 2026

Last updated: May 20, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

The GLP-1 receptor agonist class encompasses semaglutide, tirzepatide, retatrutide, dulaglutide, and liraglutide—each with distinct mechanisms, potency profiles, and clinical efficacy data. Understanding these differences is foundational to informed treatment conversations with qualified healthcare providers.

Beyond branded options, patients increasingly explore compounded formulations for cost and access. However, selecting among GLP-1 variants requires more than efficacy data—it demands attention to individual biomarkers, genetic predispositions, and treatment goals to support genuinely personalized care.

The GLP-1 Class: Mechanism, Potency, and Clinical Profiles

GLP-1 receptor agonists work by mimicking glucagon-like peptide-1, a hormone that regulates blood glucose and satiety. Semaglutide and liraglutide are selective GLP-1R agonists; tirzepatide and retatrutide activate both GLP-1R and GIPR, dual pathways offering greater weight and glucose effects in clinical trials.

Semaglutide is available as weekly injection (Ozempic, Wegovy) or oral tablet (Rybelsus). Tirzepatide is injected weekly (Mounjaro, Zepbound). Dulaglutide (Trulicity) is weekly injection. Retatrutide, triple agonist combining GLP-1R, GIPR, and GCR pathways, remains under investigation. Compounded versions of semaglutide and tirzepatide are accessible through licensed 503A pharmacies.

Comparative GLP-1 Options: Efficacy, Frequency, and Route

Clinical trials show tirzepatide achieving greater A1C reduction and weight loss than semaglutide at equivalent doses. Retatrutide triple agonist data suggests even larger glycemic and weight benefits, though clinical availability remains limited. Choice among agents depends on efficacy targets, injection tolerance, and individual response patterns informed by biomarker context.

GLP-1 Agent	Dosing Frequency	Primary Route	Mechanism	Key Clinical Outcome Data
Semaglutide	Weekly	Injection or Oral	GLP-1R selective	A1C reduction ~1.5–1.8%, weight loss 5–15%
Tirzepatide	Weekly	Injection	GLP-1R + GIPR dual	A1C reduction ~2.0–2.5%, weight loss 15–22%
Retatrutide	Weekly	Injection	GLP-1R + GIPR + GCR triple	A1C reduction ~2.0–2.7%, weight loss 24%+ (phase 3)
Dulaglutide	Weekly	Injection	GLP-1R selective	A1C reduction ~1.5%, weight loss 2–4%
Liraglutide	Daily	Injection	GLP-1R selective	A1C reduction ~1.5%, weight loss 2–3%

Genetic Predispositions in Peptide Pathways: Beyond Clinical Trials

Individual genetic variation in GLP-1 receptor (GLP1R), GIP receptor (GIPR), melanocortin-4 receptor (MC4R), and FTO genes shapes how bodies respond to GLP-1 agonist therapy. Variants in rs6923761 (GLP1R), rs1800437 (GIPR), rs17782313 (MC4R), and rs9939609 (FTO) influence receptor sensitivity and metabolic regulation, creating physiologic diversity beyond trial averages.

The Precision Peptide Genetic Test examines these predispositions to reveal how your peptide signaling pathways may differ from population norms. This information should be interpreted with a qualified healthcare provider—not to predict exact medication response, but to provide context for personalized treatment discussions and help optimize selection among available GLP-1 options.

Provider Decision Framework: Who Benefits from Which GLP-1 Class Member

Selecting among GLP-1 options requires integration of clinical efficacy data, individual risk factors, tolerability history, access, and cost. Patients with type 2 diabetes and obesity may benefit from dual agonists (tirzepatide); those seeking oral convenience may consider compounded oral semaglutide; daily-injection preference patients may discuss liraglutide or dulaglutide.

Genetic predisposition data—especially variants indicating robust GIPR or GLP1R signaling—can anchor these conversations with evidence of individual variation. Compounded semaglutide and tirzepatide through licensed 503A pharmacies offer cost-effective alternatives to branded formulations, extending access for patients for whom standard options are prohibitively expensive or geographically inaccessible.

How PlexusDx Supports a More Personalized Approach

PlexusDx Precision Peptide Genetic Testing examines four key genetic variants (GLP1R rs6923761, GIPR rs1800437, MC4R rs17782313, FTO rs9939609) that influence peptide receptor function and metabolic capacity. This biomarker context may help provide crucial nuance in GLP-1 agent selection conversations—revealing whether your genetic profile suggests stronger receptor signaling potential or metabolic barriers that might inform choice between selective versus dual agonists.

The genetic test does not predict which branded or compounded GLP-1 drug will work best for you. Rather, it reveals predispositions in peptide pathways that should be interpreted with a qualified healthcare provider. Patients with favorable GIPR variants, for example, might be candidates for dual-agonist therapy like tirzepatide or retatrutide; those with FTO risk alleles may benefit from agents with robust weight-management outcomes.

Armed with genetic predisposition context and clinical efficacy data, you can have a more informed conversation with your provider about whether semaglutide, tirzepatide, or another GLP-1 option aligns with your physiology, treatment goals, and access constraints. PlexusDx compounded semaglutide injection ($149/mo) and compounded tirzepatide injection ($249/mo) from licensed 503A pharmacies extend affordable access once your provider recommends the best agent for you.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $279/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.